Regulus (RGLS) Future Price to Earnings
The expected price-to-earnings multiple of Regulus Therapeutics (RGLS) correlates with its scientific alliances with pharma behemoths to combat renal pathologies. Diversified oligonucleotide supplies ensure the continuity of research. Future revenues are based on the commercialization of microRNA therapy for rare genetic diseases. The value of 0.00 serves as the current parameter value, capturing the current asset valuation phase on this chart.
Financial and market metric breakdowns for Regulus (RGLS)
- current price and projected stock value:
- market capitalization details:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Regulus Therapeutics|RGLS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Regulus Therapeutics|RGLS - Company Cumulative Indebtedness|Debts to Book Capitalization Regulus Therapeutics, Inc.|RGLS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Regulus Therapeutics|Quick Liquidity regulusrx.com
- financial results and valuation multiples details:
RGLS - Final Profit|Projected Future Earnings Regulus Therapeutics|RGLS - P/E Multiple|Future Price to Earnings Regulus Therapeutics Inc|RGLS - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Regulus Therapeutics, Inc.|RGLS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Regulus Therapeutics|RGLS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months regulusrx.com|RGLS - Net earnings per one share growth for the current year|Earnings growth forecast for next year Regulus Therapeutics
Summary company analysis:Regulus Therapeutics Inc.
Portfolio managers are evaluating the operating model of Regulus Therapeutics (RGLS) through the company's forward P/E ratio, which compares current market capitalization with expected net income to determine the asset's degree of overbought status. The value of 0.00 on the chart reflects market expectations amid a lack of revenue and a dependence on R&D, where any gap between the price and actual successes in RNA therapy signals high volatility.
Direct competitors
Projected Price to Earnings TEM (Tempus Labs)|Forward P/E Multiple Qiagen NV (QGEN)|Future Price to Earnings Ionis Pharma IONS|Repligen Inc. - Future Price to Earnings|RNA: Projected Price to Earnings|CRSP - Forward P/E Multiple|GeneDx (WGS) - Future Price to Earnings|RARE - Market Cap to Projected Earnings|Projected Price to Earnings BEAM|SRPT: Future Price to Earnings Multiple|Projected Price to Earnings TWST (Twist Bioscience)|Market Cap to Future Earnings Ratio TXG|Forward P/E Multiple NTLA (Intellia Therapeutics, Inc.)|Future Price to Earnings Multiple STOK|BioLife Corp - Forward P/E Multiple|Projected Price to Earnings Ratio Wave Pharma|Maze Therapeutics Inc (MAZE) - Future Price to Earnings|sionnatx.com - Future Price to Earnings Multiple|PRME (Prime Medicine) - Forward P/E Multiple|Forward P/E Multiple Taysha Gene Therapies Inc|Future Price to Earnings uniQure Corp (QURE)|MGTX: Price to Expected Earnings Ratio|Forward P/E Multiple RGNX (REGENXBIO Inc.)|solidbio.com (SLDB) - Projected Price to Earnings Ratio|OCGN: Projected Price to Earnings|PACB - Forward P/E Multiple|BNTC (Benitec) - Projected Price to Earnings|DSGN: Market Cap to Future Earnings Ratio|RCKT (Rocket Pharmaceuticals) - Forward P/E Multiple|4dmoleculartherapeutics.com (FDMT) - Market Cap to Projected Earnings|Forward P/E Multiple LXEO|Projected Price to Earnings korrobio.com KRRO|Future Price to Earnings Editas EDIT|Market Cap to Projected Earnings Silence Therapeutics Corp (SLN)|PRQR - Future Price to Earnings|Future Price to Earnings Multiple CDXS (Codexis, Inc.)|SGMO: Forward P/E Multiple|Forward Price to Earnings Multiple Nautilus Bio NAUT|Future Price to Earnings Metagenomi, Inc|Future Price to Earnings DTIL|Future Price to Earnings Generation Bio Co. (GBIO)|Market Cap to Projected Earnings boundlessbio.com|Forward P/E Multiple XCUR (Exicure)|IMNN: Price to Future Earnings Ratio|PHIO - Future Price to Earnings|MBIO (Mustang Bio, Inc.) - Price to Future Earnings Ratio|RNAZ: Forward P/E Multiple|Bionano Genomics (BNGO) - Forward P/E Multiple|Future Price to Earnings Applied DNA Sciences, Inc.|BLUE: Future Price to Earnings Multiple|Forward P/E Multiple IPA|OMGA - Projected Price to Earnings Ratio|Forward P/E Multiple OMIC (Singular Genomics Systems)|Forward Price to Earnings Multiple syros.com|TBIO: Projected Price to Earnings|TCON - Forward P/E Multiple|Unity Bio (UBX) - Future Price to Earnings
